Pusceddu Claudio, Faiella Eliodoro, Cau Claudio, Rinaldi Pierluigi, Melis Luca, Marsico Salvatore
Mater Olbia Hospital, Department of Radiology, Olbia, Italy
Campus Bio Medico, Department of Radiology, Rome, Italy
Diagn Interv Radiol. 2025 Jul 8;31(4):372-376. doi: 10.4274/dir.2024.242956. Epub 2024 Oct 21.
To assess the effectiveness and safety of computed tomography (CT)-guided cryoablation for treating adrenal metastases (AMs).
This study included 12 patients treated with 13 CT-guided cryoablation procedures for AMs between 2016 and 2020. Patients were selected based on specific criteria, including tumor size ≤5 cm and suitability for surgery. Procedures were performed by expert radiologists, with comprehensive monitoring for complications and regular post-treatment evaluations.
The primary technical success rate was 91.7%, with a secondary success rate of 100% following repeat procedures. Over an 8-24-month follow-up period, local tumor recurrence was observed in 16.7% of patients, and systemic progression occurred in five (41.6%) patients. The average overall survival duration was 26.4 ± 5.6 months.
CT-guided cryoablation is a feasible and effective treatment option for AMs, demonstrating high technical success rates and manageable complications.
This study highlights CT-guided cryoablation as a promising treatment for AMs, offering a minimally invasive alternative to surgery with good local control and safety profile. Further research, including multi-center studies, is needed to confirm these findings.
评估计算机断层扫描（CT）引导下冷冻消融治疗肾上腺转移瘤（AMs）的有效性和安全性。
本研究纳入了2016年至2020年间接受13次CT引导下冷冻消融治疗AMs的12例患者。患者根据特定标准入选，包括肿瘤大小≤5 cm且适合手术。手术由专业放射科医生进行，对并发症进行全面监测并定期进行治疗后评估。
主要技术成功率为91.7%，重复手术后二次成功率为100%。在8至24个月的随访期内，16.7%的患者出现局部肿瘤复发，5例（41.6%）患者出现全身进展。平均总生存时间为26.4±5.6个月。
CT引导下冷冻消融是治疗AMs的一种可行且有效的治疗选择，显示出较高的技术成功率和可控制的并发症。
本研究强调CT引导下冷冻消融是一种有前景的AMs治疗方法，为手术提供了一种微创替代方案，具有良好的局部控制和安全性。需要进一步研究，包括多中心研究，以证实这些发现。
